| 词条 | Vatelizumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 470629425 | type = mab | image = | alt = | mab_type = mab | source = zu | target = integrin alpha 2 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1238217-55-4 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | chemical_formula = | molecular_weight = }}Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1] It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format = PDF }}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }} {{monoclonals for immune system}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite journal |vauthors=Mozaffari S, Nikfar S, Abdollahi M |title=Inflammatory bowel disease therapies discontinued between 2009 and 2014 |journal=Expert Opin Investig Drugs |volume=24 |issue=7 |pages=949–56 |date=2015 |pmid=25861835 |doi=10.1517/13543784.2015.1035432 |url=}} 2 : Monoclonal antibodies|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。